June 13, 2021
FinanzNachrichten
Italy Suspends AstraZeneca COVID-19 Vaccine For People Under 60 Yrs, After Teenager Dies
LONDON (dpa-AFX) - Italy suspended the use of the AstraZeneca COVID-19 vaccine for people under 60 ye... See more »
611 Followers on Owler
Ambrx
Ambrx is a biopharmaceutical company that discovers and develops antibody-drug conjugates and immuno-oncology therapies for cancer diseases. Read more
Chairman & CEO
Feng Tian
Missing a competitor? Contribute!
AVEO is Ambrx's biggest rival. AVEO was founded in Boston, Massachusetts} in 2001. Like Ambrx, AVEO also competes in the Biotechnology sector. Compared to Ambrx, AVEO generates $7.2M more revenue.
Weigh-in!
Help the Owler community know moreTrending News for Ambrx and Ambrx's Competitors
June 13, 2021
Competition Policy International
AbbVie Unit To Face Antitrust Trial On Alzheimer Drug
AbbVie unit Forest Laboratories and another drug company lost their bid Friday to head off an antitru... See more »
June 12, 2021
Pharmabiz
GeneTx, Ultragenyx receive UK MHRA approval to begin phase 1/2 study of GTX102 to treat Angelman syndrome
GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical announced that the UK Medicines and Healthca... See more »
Ambrx Quarterly and Annual Revenue
Coming soon for Ambrx!
Annual Revenue
Ambrx Acquisitions
No recent acquisitions found related to Ambrx
Ambrx Funding History
Since Ambrx was founded in 2003, it has participated in 9 rounds of funding. In total Ambrx has raised $438.2M. Ambrx's last funding round was on Nov 2020 for a total of $200.0M
ROUND
FUNDING DATE
AMOUNT
INVESTORS
Debt - PPP (CARES Act)
May 2020
$1M - $2M
IPO
May 2014
$86.3M
Since Ambrx was founded in 2003, it has participated in 9 rounds of funding. In total Ambrx has raised $438.2M. Ambrx's last funding round was on Nov 2020 for a total of $200.0M
Ambrx Investments
No recent investments found related to Ambrx
Ambrx News
December 10, 2020MarketScreener
Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium
(marketscreener.com) SAN DIEGO, Dec. 10, 2020 /PRNewswire/ -- Ambrx Inc., a clinical-stage biopharmac... See more »
November 27, 2020Global Legal Chronicle
Ambrx Inc.'s US$200 Million Crossover Financing Round
Wilson Sonsini Goodrich & Rosati advised WuXi AppTec Co. on the deal. Ambrx Inc., a portfolio company... See more »
November 24, 2020Endpoints News
After 5 quiet years, a former Scripps spinout raises $200M and announces plans to try again at an IPO
The first time San Diego biotech Ambrx tried to go public in 2014, they failed and the company's boar... See more »
November 23, 2020MedCity News
$200M investment to advance clinical programs for Ambrx
The San Diego-based biopharma firm has several oncology therapies in development and has partnered in... See more »
November 10, 2020socalTECH
Ambrx Raises $200M More
San Diego-based biopharmaceuticals developer Ambrx has raised $200M in a funding round, according to ... See more »
November 9, 2020FinSMEs
Ambrx Closes US$200M Crossover Financing Round
Ambrx Inc., a San Diego, CA-based clinical-stage...... See more »
January 17, 2020Global Legal Chronicle
Sino Biopharma's Collaboration with Ambrx, Inc
Sidley Austin LLP represented Ambrx, Inc in its collaboration with Sino Biopharma. Ambrx Inc., a clin... See more »
Ambrx Press Releases
September 29, 2016freePRnow
Therapeutics development for Lipodystrophy by companies -Pipeline Review,H2 2016
Lipodystrophy Pipeline Review, H2 2016 Global Markets Direct's, Lipodystrophy - Pipeline Review, H2 2... See more »
August 12, 2016PR Newswire
Global Cancer Immunotoxins Market & Clinical Pipeline Insight Report 2020 - Research and Markets
DUBLIN, August 12, 2016 /PRNewswire/ -- Research and Markets has announced the addition of the "Globa... See more »
July 21, 2016Business Wire
C-X-C Chemokine Receptor Type 4 Pipeline Review, H1 2016 - Research and Markets
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "C-X-C Chemokine Rece... See more »
June 2, 2016Business Wire
Global Obesity Pipeline Report H1 2016 - Review of 98 Companies & Drug Profiles - Research and Markets
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Obesity - Pipeline R... See more »
May 26, 2016Blackbird
Despite Stunning Clinical Results with CD19-targeted CAR T-cells, Many Major Pharmaceutical Companies Have not Embarked on This Field of Adoptive Cell Therapy - Research and Markets
DUBLIN, May 27, 2016 /PRNewswire/ - Research and Markets has announced the addition of the "T-Cell Re... See more »
April 19, 2016Business Wire
Global Nasopharyngeal Cancer Pipeline Review 2016 - 17 Companies 32 Drug Profiles - Research and Markets
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Nasopharyngeal Cance... See more »
March 25, 2016PR Newswire
WuXi Biologics Congratulates Ambrx and ZMC for Successful Dosing of a Novel Antibody-Drug Conjugate in Australia
SHANGHAI, March 25, 2016 /PRNewswire/ -- WuXi Biologics, a wholly-owned subsidiary of WuXi AppTec (Wu... See more »
Social Media
Ambrx Headquarters
Trending Companies
IN THE NEWS
RBC | Xaar | Micron | Union Pacific | Cabot Oil & Gas | Occidental | Albemarle | Xilinx | Teamworthy | Caterpillar | Nokia | WWE | Lotus Enterprises | Baltcom | L&T | AutoZone | Suzlon | Rimba Raya | Quest Diagnostics | Beaverton Foods | King | Zimmer Biomet | Mohegan Sun | Lowenstein Sandler | Sempra | Mercedes-Benz | Vince | POOLCORP | SKS Business Services | ServiceNow | EOG Resources | JPMorgan Chase | Inovio | Global Blue | Boston Scientific | Allstate | Home Depot | Emerson Electric | Schall Law Firm | The GEO Group | Kraft Heinz | CME Group | Skyworks | Caesars Entertainment | Triller | Discovery | AT&T | Endeavour Silver | TE Connectivity | Bruker
PEOPLE ALSO VIEWED
Polyplus-transfection | Fastest Labs | ViraTherapeutics | Vitel Lab | Galectin | Cytogene Research & Development | Quay Pharma | Transcenta | MEDomics | Cordblood America | F-star | NexImmune | Agile Therapeutics | Alpha Genomix Laboratories | Novigenix | InTouch Follow-Up | Internet Insurance Group | Varcons | Stuart Business Systems | Florida Natural Flavors | Rapid Dose Therapeutics Corp. | Quantum Pharma Plc | Creative Biolabs | Krishi Mitra Biotech Research Center | Nonacus | Cisilion | Seafoodia | Movix | Installation Technicians | Epic Pharma
Ambrx Summary
ABOUT
Overview
Ambrx is a biopharmaceutical company that discovers and develops antibody-drug conjugates and immuno-oncology therapies for cancer diseases. Ambrx was founded in 2003. Ambrx's headquarters is located in La Jolla, California, USA 92037. It has raised 4...
CEO
Ambrx's Chairman & CEO, Feng Tian, currently has an approval rating of 86%. Ambrx's primary competitors are AVEO, Celldex & Almac.Website
ambrx.comFrequently Asked Questions about Ambrx
When was Ambrx founded?
Ambrx was founded in 2003Who is Ambrx's CEO?
Ambrx's CEO is Feng TianHow much revenue does Ambrx generate?
Ambrx generates $ < 1M in revenueHow much funding does Ambrx have?
Ambrx has historically raised $438.2M in funding
Where is Ambrx's headquarters?
Ambrx's headquarters is in La Jolla California, USAWhat sector does Ambrx operate in?
Ambrx is in Biotechnology, PharmaceuticalsWho are Ambrx's competitors?
Ambrx's top competitors are AVEO, Celldex, Almac
